Paul Stoffels, J&J CSO (Andrew Harnik/AP Images)

J&J sci­ence lead Paul Stof­fels set to re­tire amid brain trust shake­up at world's largest drug­mak­er

Paul Stof­fels, the sci­en­tif­ic lead be­hind J&J’s re­fresh of its hal­lowed Janssen unit and the cre­ation of the com­pa­ny’s sin­gle-shot Covid-19 vac­cine, will re­tire at the end of the year, join­ing CEO Alex Gorsky on the way out the door and set­ting up a new era of lead­er­ship at the in­dus­try’s biggest drug­mak­er.

As the man most re­spon­si­ble for J&J’s hard piv­ot back in­to R&D over the course of the past decade, Stof­fels was re­spon­si­ble for prop­ping up an on­col­o­gy R&D unit that ranks among the largest in the in­dus­try as well as dri­ving J&J’s ef­forts across a broad range of ther­a­peu­tic ar­eas.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.